Skip to main content

isavuconazole (Cresemba®)

 

Following a full submission

AWMSG advice

Status: Recommended

Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list / contract price is equivalent or lower than the WPAS price.

 Final Recommendation: isavuconazole (Cresemba) 2433 (PDF, 415Kb)
 Appraisal Report: isavuconazole (Cresemba) 2433 (PDF, 708Kb)

Medicine details

Medicine name isavuconazole (Cresemba®)
Formulation 100 mg capsule; 200 mg powder for concentrate for solution for infusion
Reference number 2433
Indication

Treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate

Company Basilea Pharmaceuticals Ltd
BNF chapter Infections
Submission type Full
Status Recommended
Advice number 3616
NMG meeting date 02/11/2016
AWMSG meeting date 07/12/2016
Ratification by Welsh Government 22/12/2016
Date of issue 04/01/2017
Date of last review September 2020
Commercial arrangement WPAS
Follow AWTTC: